Meta-Analysis
Copyright ©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 91457
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.91457
Table 1 Details of published case reports
Number
Ref.
Country
Age
Sex
Comorbidities
MELD score
Complications
Organ support
Outcome
1Subramanian et al[28], 2005India35MNone17NoneNoneAlive
2Vinodh et al[29], 2005India19MNone30ShockVasopressorsAlive
3Penafiel et al[25], 2006Singapore69MNoneNAGI bleed, HE RRT, IMV, MARSAlive
4Ling et al[22], 2007Singapore55MNoneNANoneNoneAlive
5Gasperino et al[19], 2007United States69FCAD30HEVasopressors, RRT, IMVAlive
6Osorio et al[23], 2008Canada31FNoneNAMODSNADead
7Sedhain et al[27], 2011Nepal20FNone31ARFNoneAlive
8Agarwal et al[13], 2011India33MNone25HE, seizuresNoneAlive
9Jhamb et al[21], 2011India19MNone27HE, shock, GI bleedIMVAlive
10Abeysekera et al[12], 2012Sri Lanka52FHypertensionNAHENoneAlive
11Arora et al[14], 2015India22MNone10Minor bleeding, HENoneAlive
12Dalugama et al[16], 2017Sri Lanka53MNone16NoneNoneAlive
13Dalugama et al[17], 2018Sri Lanka43FDiabetes, dyslipidaemiaNAShock, HE, AKI, GI bleedRRTAlive
14Samarasekara et al[26], 2018Sri Lanka38FNone26DVT, AKINoneAlive
15Galante et al[18], 2019Canada49FNoneNAShock, AKI, HEVasopressors, RRT, IMVAlive
16Paul et al[24], 2020India50MAlcoholic liver disease29HENoneAlive
17Lewis et al[30], 2020United States23FNoneNAHENoneAlive
18Chikkala et al[15], 2021India29FNone38HEVasopressors, RRT, IMVAlive
19Gunasekera et al[20], 2022Sri Lanka54FHypertension, diabetes36Bleeding, HE, AKIVasopressors, RRT, IMVAlive
Table 2 Baseline patient parameters
Parameter of interest
Frequency (%)
Age (yr), median 38 (IQR 26.5)
SexFemales 10 (52.6%)
Country of origin
India7 (36.8)
Sri Lanka5 (26.3)
Canada2 (10.5)
Singapore2 (10.5)
United States of America2 (10.5)
Nepal1 (5.3)
Diagnostic methodology
Only serology (IgM)14 (73.7)
Only antigen (NS1 Ag)3 (15.8)
Both antigen (NS1 Ag) and serology (IgM)2 (10.5)
Capillary leak syndrome 11 (57.9)
Dengue shock syndrome 15 (78.9)
Diagnosis of dengue to ALF in days, median (IQR Q3-Q1)4.5 (1)
Table 3 Baseline laboratory parameters and hospital course
Parameter of interest
Frequency (%)
Hematocrit, median 42.60 (IQR 15.15)
Total leucocyte count (per µL), median 5800 (IQR 5800)
Platelet count (per µL), median 25500 (IQR 28250)
AST (U/L), median 4625 (IQR 11902.5)
ALT (U/L), median 3100 (IQR 2607)
AST/ALT ratio, median 2.45 (IQR 1.75)
Alkaline phosphatase (IU/L), median 191 (IQR 117)
Total bilirubin (mg/dL), median 5.5 (IQR 5.63)
Direct bilirubin (mg/dL), median 2.55 (IQR 2.75)
INR, median 2.13 (IQR 1.79)
Albumin (g/L), median 2.85 (IQR 0.48)
Creatinine (mg/dL), median 1.63 (IQR 2.12)
MELD score, median 27.5 (IQR 5)
Days of ICU stay, median 6 (IQR 2)
Specific therapies
N-acetyl cysteine 6 (31.6)
Types of organ support
Vasopressors 8 (42.1)
Renal replacement therapy 6 (31.6)
Ventilation6 (31.6)
MARS1 (5.3)
Organ failure 14 (73.7)
Neurological10 (52.6)
Cardiac8 (42.1)
Renal7 (36.8)
Respiratory
Complications
Hepatic encephalopathy13 (68.4)
Bleedings3 (15.8)
DVT1 (5.3)
Liver transplantation2 (10.5)
Death1 (5.3)